Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04374877. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT04374877
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Enrollment
- 145 participants
Conditions and interventions
Conditions
Interventions
- CHS-388 Drug
- Pembrolizumab Drug
- Toripalimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2020
- Primary completion
- May 27, 2025
- Completion
- Jun 4, 2025
- Last update posted
- Jul 14, 2026
2020 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | — |
| University of Southern California (USC) - Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | — |
| University of Miami Leonard M. Miller School of Medicine (UMMSM) | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Health System (UMHS) | Ann Arbor | Michigan | 48109 | — |
| Washington University School of Medicine - St. Louis | St Louis | Missouri | 63110 | — |
| Roswell Park | Buffalo | New York | 14263 | — |
| Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH) | New York | New York | 10029 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)) | Pittsburgh | Pennsylvania | 15232 | — |
| Vanderbilt University Medical Center (VUMC) | Nashville | Tennessee | 37232 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04374877, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04374877 live on ClinicalTrials.gov.